D.A. Davidson & CO. Purchases Shares of 57,736 Perrigo Company plc (NYSE:PRGO)

D.A. Davidson & CO. purchased a new stake in shares of Perrigo Company plc (NYSE:PRGO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 57,736 shares of the company's stock, valued at approximately $1,619,000.

Other institutional investors have also added to or reduced their stakes in the company. Headlands Technologies LLC boosted its holdings in shares of Perrigo by 1,942.0% during the fourth quarter. Headlands Technologies LLC now owns 1,409 shares of the company's stock worth $36,000 after purchasing an additional 1,340 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Perrigo by 176.9% during the first quarter. Parallel Advisors LLC now owns 1,714 shares of the company's stock worth $48,000 after purchasing an additional 1,095 shares during the period. First Horizon Advisors Inc. boosted its holdings in shares of Perrigo by 138.3% during the first quarter. First Horizon Advisors Inc. now owns 1,754 shares of the company's stock worth $49,000 after purchasing an additional 1,018 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Perrigo by 62.0% during the first quarter. Fifth Third Bancorp now owns 2,218 shares of the company's stock worth $62,000 after purchasing an additional 849 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of Perrigo by 110.4% during the first quarter. Blue Trust Inc. now owns 2,619 shares of the company's stock worth $73,000 after purchasing an additional 1,374 shares during the period. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Perrigo from a "hold" rating to a "buy" rating in a report on Saturday. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $33.00.

Perrigo Stock Performance

Shares of PRGO opened at $26.74 on Tuesday. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.36 and a quick ratio of 1.28. Perrigo Company plc has a one year low of $23.14 and a one year high of $30.93. The company has a 50-day simple moving average of $26.57 and a two-hundred day simple moving average of $26.03. The firm has a market capitalization of $3.68 billion, a PE ratio of -20.41 and a beta of 0.45.

Perrigo (NYSE:PRGO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.04. Perrigo had a negative net margin of 4.16% and a positive return on equity of 8.93%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the business earned $0.29 earnings per share. The business's revenue was down 3.5% on a year-over-year basis. On average, analysts anticipate that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Stockholders of record on Friday, May 30th were issued a dividend of $0.29 per share. The ex-dividend date was Friday, May 30th. This represents a $1.16 annualized dividend and a dividend yield of 4.34%. Perrigo's payout ratio is -88.55%.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.